Association between pain sensitivity thresholds and movement disorders in patients with schizophrenia
Authors
A.A. Agarkov
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
V.V. Tiguntsev
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
A.E. Pershina
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
E.S. Beltyukova
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
V.D. Kosterin
Federal State Budgetary Institution “V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology” of the Ministry of Health of the Russian Federation, St. Petersburg, Russian Federation
E.G. Kornetova
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation
https://doi.org/10.26617/1810-3111-2026-3(132)-25-36
Journal: Siberian Herald of Psychiatry and Addiction Psychiatry. 2026; 3 (132): 25-36.
Abstract
Background. Schizophrenia, as a chronic psychotic disorder, requires long-term antipsychotic therapy based primarily on the blockade of dopamine D2 receptors. Despite the widespread adoption of second-generation antipsychotics, such therapy carries a high risk of antipsychotic-induced extrapyramidal movement disorders, which significantly impair quality of life, increase the risk of somatic complications, and reduce treatment adherence. Recent meta-analyses indicate that the incidence of antipsychotic-induced extrapyramidal movement disorders remains high, yet their relationship with pain sensitivity thresholds has not been sufficiently studied. Objective. To investigate the association between pain sensitivity thresholds and the severity of movement disorders in patients with schizophrenia. Materials and Methods. A clinical-psychopathological assessment was conducted on 60 patients with schizophrenia (29 women and 31 men) aged 18 to 55 years. Psychopathological symptom severity was assessed using the PANSS scale, and the severity of movement disorders was evaluated using the Simpson-Angus Scale. “The method for the quantitative assessment of individual pain thresholds” was employed to objectively measure pain sensitivity parameters. The findings were analyzed using statistical methods. Results. At the first stage of the study, pain sensitivity indicators were analyzed across subgroups with varying levels of movement disorders (normal, mild, moderate, and severe). It was demonstrated that lower pain threshold levels differed statistically significantly among patients with different degrees of movement disorders. At the second stage, a correlation analysis between the total Simpson-Angus Scale score and the both upper and lower pain thresholds was performed. The total Simpson–Angus scale score showed a moderate yet statistically significant positive correlation with lower pain threshold levels in the study group. Conclusion. The observed association between the lower pain threshold and parkinsonian symptoms suggests shared neurochemical mechanisms regulating motor function and nociception in schizophrenia, thereby opening new avenues for stratifying the risk of somatic complications and personalizing antipsychotic therapy based on the patient’s individual sensorimotor profile.
Keywords: schizophrenia, pain sensitivity, movement disorders.
Contacts
This email address is being protected from spambots. You need JavaScript enabled to view it.
Materials
For citation: Agarkov A.A., Tiguntsev V.V., Pershina A.E., Beltyukova E.S., Kosterin V.D., Kornetova E.G. Association between painsensitivity thresholds and movement disorders in patients with schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry.2026; 3 (132): 25-36. https://doi.org/10.26617/1810-3111-2026-3(132)-25-36
REFERENCES
- Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017 Jun 29;13:757-777. https://doi.org/10.2147/TCRM.S117321. PMID: 28721057; PMCID: PMC5499790.
- Shiraiwa N, Tamaoka A, Ohkoshi N. Clinical features of drug-induced Parkinsonism. Neurol Int. 2018 December 20;10(4):7877. https://doi.org/10.4081/ni.2018.7877. PMID: 30687468; PMCID: PMC6322048.
- Strassnig M, Rosenfeld A, Harvey PD. Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectr. 2018 Dec;23(6):370-377.https://doi.org/10.1017/S1092852917000542.
- Kornetova EG, Semke AV. Сontemporary issues and perspectives on the studying of schizophrenia with negative symptoms leading. Bulletin of Siberian Medicine. 2014;13(1):5-13.https://doi.org/10.20538/1682-0363-2014-1-5-13 (inRussian).
- KornetovaEG, SemkeAV. To the problem of first psychotic episode therapy. Siberian Herald of Psychiatry and Addiction Psychiatry. 2009; 55(4): 17-19 (in Russian).
- Walther S, Mittal VA. Motor System Pathology in Psychosis. Curr Psychiatry Rep. 2017;19(12):97. https://doi.org/10.1007/s11920-017-0856-9.
- van Harten PN, Walther S, Kent JS, Sponheim SR, Mittal VA. The clinical and prognostic value of motor abnormalities in psychosis, and the importance of instrumental assessment. Neurosci Biobehav Rev. 2017September;80:476-487. https://doi.org/10.1016/j.neubiorev.2017.06.007.
- Корнетов Н.А., Залевский Г.В. К проблеме взаимоотношения шизоидии и шизофрении. Журнал невропатологии и психиатрии им. С.С. Корсакова. 1990. Т. 90, № 2. С. 135-144. Kornetov NA, Zalevskiy GV. On the relationship between schizoidia and schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 1990; 90(2): 135-144 (in Russian).
- Tsapakis EM, Mitkani CA, Fountoulakis KN. Neurological soft signs and schizophrenia. CNS Spectr. 2023 March;28(6):657-661.https://doi.org/10.1017/S1092852923001189.
- Pershina AE, Kornetov AN, Galkin SA, Kornetova EG. Motor dysfunctions as an intermediate phenotype of schizophrenia: a systematic review. S.S. Korsakov Journal of Neurology and Psychiatry. 2026; 126 (8): 51-58.https://doi.org/10.17116/jnevro202612608151 (in Russian).
- Hirjak D, Meyer-Lindenberg A, Kubera KM, Thomann PA, Wolf RC. Motor dysfunction as research domain in the period preceding manifest schizophrenia: A systematic review. Neurosci Biobehav Rev. 2018 Apr;87:87-105. https://doi.org/10.1016/j.neubiorev.2018.01.011. Epub2018 Feb 20. PMID: 29410313.
- Levchenko A, Kanapin A, Samsonova A, Fedorenko OYu, Kornetova EG, Nurgaliev T, Mazo GE, Semke AV, Kibitov AO, Bokhan NA, Ivanova SA, Gainetdinov RR A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. Prog Neuropsychopharmacol Biol Psychiatry. 2021 March;105:110134.https://doi.org/10.1016/j.pnpbp.2020.110134.
- Peralta V, Cuesta MJ. Motor abnormalities: From neurodevelopmental to neurodegenerative through “functional” (neuro)psychiatric disorders. Schizophr Bull. 2017 Sep 1;43(5):956-971.https://doi.org/10.1093/schbul/sbx089. PMID: 28911050; PMCID: PMC5581892.
- Kornetova EG, Galkin SA, Kornetov AN, Ivanova SA, Bokhan NA. Phenotypes of schizophrenia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2025; 2 (127): 15-32. https://doi.org/10.26617/1810-3111-2025-2(127)-15-32 (in Russian).
- Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychological Medicine.2009. November;39(7):1065–1076. https://doi.org/10.1017/S0033291708004716.
- Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and Parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull. 2010 Jul;36(4):723-31. https://doi.org/10.1093/schbul/sbn146. Epub 2008 Nov 5. PMID: 18990712; PMCID: PMC2894597.
- Mittal VA, Dean DJ, Bernard JA, Orr JM, Pelletier-Baldelli A, Carol EE, Gupta T, Turner J, Leopold DR, Robustelli BL, Millman ZB. Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective. Schizophr Bull. 2014 Nov;40(6):1204-15. https://doi.org/10.1093/schbul/sbt199. Epub 2013 Dec 27. PMID: 24375457; PMCID: PMC4193696.
- Viher PV, Stegmayer K, Bracht T, Federspiel A, Bohlhalter S, Strik W, Wiest R, Walther S. Neurological soft signs are associated with altered white matter in patients with schizophrenia. Schizophr Bull. 2022 Jan 21;48(1):220-230.https://doi.org/10.1093/schbul/sbab089. PMID: 34355246; PMCID: PMC8781326.
- Zhao Q, Li Z, Huang J, Yan C, Dazzan P, Pantelis C, Cheung EF, Lui SS, Chan RC. Neurological soft signs are not "soft" in brain structure and functional networks: evidence from ALE meta-analysis. Schizophr Bull. 2014 May;40(3):626-41. https://doi.org/10.1093/schbul/sbt063. Epub 2013 May 13. PMID: 23671197; PMCID: PMC3984512.
- Lozano-Goupil J, Parmacek S, Gold JM, Corlett PR, Strauss GP, Schiffman J, Ellman LM, Walker EF, Powers A, Woods SW, Waltz JA, Silverstein SM, Mittal VA. Spontaneous head movements during virtual clinical interviews help predict 12-months clinical outcomes in youth at clinical high risk for psychosis. Schizophrenia (Heidelb). 2025 Nov 19;11(1):137. https://doi.org/10.1038/s41537-025-00683-1.
- Hirjak D, Rashidi M, Kubera KM, Northoff G, Fritze S, Schmitgen MM, Sambataro F, Calhoun VD, Wolf RC. Multimodal magnetic resonance imaging data fusion reveals distinct patterns of abnormal brain structure and function in catatonia. Schizophr Bull. 2020 Jan 4;46(1):202-210.https://doi.org/10.1093/schbul/sbz042. PMID: 31174212; PMCID: PMC6942158.
- Stubbs B, Thompson T, Acaster S, Vancampfort D, Gaughran F, Correll CU. Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies. Pain. 2015 November;156(11):2121-2131.https://doi.org/10.1097/j.pain.0000000000000304.
- Potvin S, Marchand S. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a systematic quantitative review of experimental studies. Pain. 2008 August 15;138(1):70-78.https://doi.org/10.1016/j.pain.2007.11.007. Epub 2007 Dec 21. PMID: 18160219.
- DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, Newcomer JW, Uwakwe R, Leucht S. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011 Feb;10(1):52-77. https://doi.org/10.1002/j.2051-5545.2011.tb00014.x. PMID: 21379357; PMCID: PMC3048500.
- Torregrossa LJ, Amedy A, Roig J, Prada A, Park S. Interoceptive functioning in schizophrenia and schizotypy. Schizophr Res. 2022 Jan;239:151-159. https://doi.org/10.1016/j.schres.2021.11.046. Epub 2021 Dec 8. PMID: 34891079.
- Taylor AMW, Becker S, Schweinhardt P, Cahill C. Mesolimbic dopamine signaling in acute and chronic pain: implications for motivation, analgesia, and addiction. Pain. 2016 Jun;157(6):1194-1198. https://doi.org/10.1097/j.pain.0000000000000494. PMID: 26797678; PMCID: PMC4866581.
- Dworkin RH. Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr Bull. 1994;20(2):235-248. https://doi.org/10.1093/schbul/20.2.235.
- Shin HW, Chung SJ. Drug-induced parkinsonism. J. Clinl Neurol. 2012 June;8(1):15.doi:10.3988/jcn.2012.8.1.15.
- Bannister K, Dickenson AH. The plasticity of descending controls in pain: translational probing. J Physiol. 2017 Jul 1;595(13):4159-4166. https://doi.org/10.1113/JP274165. Epub 2017 May 26. PMID: 28387936; PMCID: PMC5491855.
- Elman I, Zubieta JK, Borsook D. The missing p in psychiatric training: why it is important to teach pain to psychiatrists. Arch Gen Psychiatry. 2011 January; 68(1):12-20.https://doi.org/10.1001/archgenpsychiatry.2010.174. PMID: 21199962; PMCID: PMC3085192.
- Kornetova EG, Goncharova AA, Kornetov AN, Davydov AA, Dubrovskaya VV, Semke AV. et al. The relationship between suicidal behavior and hopelessness with akathisia in patients with schizophrenia. Suicidology. 2018;9(3):63-70.https://doi.org/10.32878/suiciderus.18-09-03(32)-63-70 (in Russian).
- Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13 (2): 261-276.
- Mosolov SN. Psychometric assessment scales for schizophrenia symptoms and the concept of positive and negative disorders. Moscow: Novyj cvet, 2001: 238(in Russian).
- Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60(1):3-38.https://doi.org/10.1016/0304-3959(94)00172-B.
- Walther S, Strik W. Motor symptoms and schizophrenia. Neuropsychobiology. 2012 July;66(2):77-92. https://doi.org/10.1159/000339456.
- PozhidaevIV, IvanovaSA. Association analysis of haplotypes and regulatory potential of serotonin receptor genes in patients with schizophrenia and tardive dyskinesia. Siberian Herald of Psychiatry and Addiction Psychiatry. 2024; 1 (122): 27-36. https://doi.org/10.26617/1810-3111-2024-1(122)-27-36 (in Russian).
- Petrescu C, Papacocea IR, Vilciu C, Mihalache OA, Vlad DM, Marian G, Focseneanu BE, Sima CT, Ciobanu CA, Riga S, Ciobanu AM. The impact of antipsychotic treatment on neurological soft signs in patients with predominantly negative symptoms of schizophrenia. Biomedicines. 2022 Nov 15;10(11):2939.https://doi.org/10.3390/biomedicines10112939. MID:36428507; PMCID: PMC9687986.
- Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018 October;17(3):330-340. https://doi.org/10.1002/wps.20579. PMID: 30192088; PMCID: PMC6127753.
- Mitsi V, Zachariou V. Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience. 2016 December 3;338:81-92.https://doi.org/10.1016/j.neuroscience.2016.05.017. Epub 2016 May 14. PMID: 27189881; PMCID: PMC5083150.
- Cornett EM, Novitch M, Kaye AD, Kata V, Kaye AM. Medication-induced tardive dyskinesia: a review and update. Ochsner J. 2017 July;17(2):162-174. https://doi.org/10.1043/TOJ-16-0108.
- Siafis S, Wu H, Wang D, Burschinski A, Nomura N, Takeuchi H, Schneider-Thoma J, Davis JM, Leucht S. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. 2023 August;28(8):3267-3277. https://doi.org/10.1038/s41380-023-02203-y.
- Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother. 2008 May;8(5):781-97. https://doi.org/10.1586/14737175.8.5.781. PMID: 18457535.
- Silverdale MA, Kobylecki C, Kass-Iliyya L, Martinez-Martin P, Lawton M, Cotterill S, Chaudhuri KR, Morris H, Baig F, Williams N, Hubbard L, Hu MT, Grosset DG; UK Parkinson's Pain Study Collaboration. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism Relat Disord. 2018 November;56:27-32. https://doi.org/10.1016/j.parkreldis.2018.06.001. Epub 2018 Jun 6. PMID: 29903584; PMCID: PMC6302227.
- Rukavina K, Leta V, Sportell, C, Ray Chaudhuri K, Nicolaou A. Pain in Parkinson’s disease: new concepts in pathogenesis and treatment. Current Opinion in Neurology. 2019 June; 32(4):579-588. https://doi.org/10.1097/WCO.0000000000000711.
- Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, Smith N, Bitter I, Gorwood P, Taipale H, Tiihonen J. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022 Jun;21(2):248-271. https://doi.org/10.1002/wps.20994. PMID: 35524619; PMCID: PMC9077617.
- Walburn J, Gray R, Gournay K, Quraishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry. 2001 October;179:300-7.https://doi.org/10.1192/bjp.179.4.300. PMID: 11581109.
- Caroff SN, Hurford I, Lybrand J, Campbell EC. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011 Feb;29(1):127-48, VIII. https://doi.org/10.1016/j.ncl.2010.10.002. PMID: 21172575; PMCID: PMC3018852.